InspireMD (NSPR)
NASDAQ:NSPR
Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$1.84
$0.06(2.18%)
At close: 4:00 PM EST
$1.84
$0.06(2.18%)
Day’s Range― - ―
52-Week Range$1.02 - $2.93
Previous CloseN/A
Volume8.46K
Average Volume (3M)102.59K
Market Cap
$53.86M
Enterprise Value$44.61M
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)103.6
Beta-0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,892,980
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit14.65
Enterprise Value/Ebitda-0.87
Forecast
1Y Price Target
$3.67Price Target Upside99.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety And EfficacyClinical trial results showing very low rates of major complications support the device's safety profile versus existing treatments and could increase clinician confidence.
Innovative Device DesignProprietary MicroNet mesh that traps plaque and reduces embolization offers a distinct clinical advantage and could encourage a shift toward a stent-first treatment approach.
Regulatory Approval And Commercial LaunchFDA premarket approval and an established US commercial launch create a clear pathway for US sales and broader physician adoption.
Bears Say
Commercial Adoption And Procedure VolumeA small number of procedures performed to date signals limited commercial uptake, which could slow revenue growth and delay broader market penetration.
Financial Condition And Funding RiskOngoing GAAP losses and persistent cash burn raise the possibility that additional capital may be required if commercial momentum does not improve.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.02 and its highest was $2.93 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $53.86M.
When is InspireMD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were InspireMD’s earnings last quarter?
Currently, no data Available
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InspireMD have?
InspireMD has 46,892,980 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (99.28% Upside)
$3.67 (99.28% Upside)
Insider Transactions
Bought Shares
Worth $217.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
-81.52%
Trailing 12-Months
Asset Growth
46.03%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
NSPR Earnings Call
Q4 2026
0:00 / 0:00
NSPR Stock 12 Month Forecast
Average Price Target
$3.67
▲(99.28% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
EDAP TMS
―
Vivani Medical
―
Xtant Medical Holdings
―
Ownership Overview
20.21% Insiders
0.04% Mutual Funds
0.82% Other Institutional Investors
78.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---